21,245 Shares in Catalent, Inc. (NYSE:CTLT) Acquired by Natixis Advisors LLC

Natixis Advisors LLC acquired a new stake in Catalent, Inc. (NYSE:CTLT - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,245 shares of the company's stock, valued at approximately $1,287,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Millennium Management LLC increased its holdings in shares of Catalent by 129.2% during the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company's stock valued at $229,416,000 after purchasing an additional 2,299,784 shares during the period. Alpine Associates Management Inc. boosted its stake in Catalent by 3.8% in the 2nd quarter. Alpine Associates Management Inc. now owns 2,061,251 shares of the company's stock valued at $115,904,000 after buying an additional 75,700 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Catalent by 14.9% during the second quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company's stock valued at $108,559,000 after acquiring an additional 250,999 shares during the period. Marshall Wace LLP increased its holdings in Catalent by 5.1% in the second quarter. Marshall Wace LLP now owns 1,792,951 shares of the company's stock valued at $100,818,000 after purchasing an additional 86,533 shares during the last quarter. Finally, ING Groep NV boosted its position in shares of Catalent by 162.5% during the third quarter. ING Groep NV now owns 1,130,504 shares of the company's stock worth $68,475,000 after buying an additional 699,851 shares during the period.

Catalent Price Performance

Catalent stock traded up $0.15 during mid-day trading on Wednesday, reaching $60.90. The company had a trading volume of 474,514 shares, compared to its average volume of 2,031,679. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50. The business has a fifty day simple moving average of $59.84 and a 200 day simple moving average of $58.39. The company has a market cap of $11.05 billion, a P/E ratio of -26.88, a P/E/G ratio of 2.44 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same period last year, the business earned ($0.10) earnings per share. The company's revenue was up 4.2% on a year-over-year basis. On average, equities research analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current year.

Insider Transactions at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company's stock, valued at $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company's stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock valued at $305,931 in the last 90 days. 0.31% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

CTLT has been the topic of several recent analyst reports. William Blair reiterated a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird restated a "neutral" rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. StockNews.com downgraded Catalent from a "hold" rating to a "sell" rating in a research report on Friday, November 22nd. Finally, Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company's stock. According to MarketBeat.com, Catalent currently has an average rating of "Hold" and an average price target of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.